| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9fedff0fbf60b638edcaba8c0cad407d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5073a0063d6be9e25c14d2af0a1ee89
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a68affb01737b30ad62b3cb58aa14206
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf18e1fee4c0021271f8ae66c64c5838 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-141
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-531 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2016-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edf09cd79261f095a89426a70179f851
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e72e542536cf350d78922f21bfd250c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da6d03c2e3457a5aeb55bfafd0ed9f15 |
| publicationDate |
2018-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3263706-A1 |
| titleOfInvention |
Agents targeting snat7 for treating cellular metabolism reprogramming-associated diseases |
| abstract |
The present application relates to therapeutic agent reducing the expression or the activity of the SNAT7 transporter, encoded by the SLC38A7 gene or one of its variants for use in the treatment of a cellular metabolism reprogramming-associated disease, preferentially a cancer depending on glutamine, more preferentially a cancer depending on glutamine activated by one or more oncogenes selected from Ras, Myc and Src, even more preferentially a cancer depending on glutamine activated by Ras. The present invention also relates to a pharmaceutical composition comprising at least one therapeutic agent for use according to the invention, or at least one expression vector according expressing said therapeutic agent for use to the invention. |
| priorityDate |
2016-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |